Newsfeeds - Spark Newswire - Page 2

Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Read More

1 minute read

argenx Q3 EPS $(4.26) Misses $(3.45) Estimate, Sales $146.49M Beat $115.68M Estimate

By Benzinga Newsdesk

Today, 10:03 AM

argenx (NASDAQ:ARGX) reported quarterly losses of $(4.26) per share which missed the analyst consensus estimate of $(3.45) by 23.48 percent. This is a 106.8 percent decrease over losses of $(2.06) per share from the same

Read More

15 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For October 12, 2022

By Benzinga Insights

Today, 10:03 AM

Upgrades

Read More

1 minute read

Immunovant’s New Candidate Provides Some Strategic Flexibility & Clarity, Analysts Say

By Vandana Singh

Today, 10:03 AM

On Wednesday, Immunovant Inc (NASDAQ:IMVT) announced a new anti-FcRn, IMVT-1402, at Roivant Sciences Ltd’s (NASDAQ:ROIV) Investor Day. IMVT-1402 is a new anti-FcRn monoclonal antibody…

Read More

1 minute read

Argenx Seeks FDA Nod For Its Flagship Neuromuscular Treatment Formulated For Subcutaneous Injection

By Vandana Singh

Today, 10:03 AM

Argenx SE (NASDAQ: ARGX) has

Read More

1 minute read

Piper Sandler Maintains Overweight on argenx, Raises Price Target to $465

By Benzinga Newsdesk

Today, 10:03 AM

Piper Sandler analyst Allison Bratzel maintains argenx (NASDAQ:ARGX) with a Overweight and raises the price target from $450 to $465.

Read More

3 minute read

Recap Of Thursday’s Biotech Catalysts – End Of the Day Summary

By Ragothaman Srinivasan

Today, 10:03 AM

The U.S. Food and Drug Administration (FDA) has accepted the Menarini Group and Radius Health’s (NASDAQ:RDUS), New Drug…

Read More

1 minute read

Morgan Stanley Maintains Overweight on argenx, Raises Price Target to $401

By Benzinga Newsdesk

Today, 10:03 AM

Morgan Stanley analyst Matthew Harrison maintains argenx (NASDAQ:ARGX) with a Overweight and raises the price target from $375 to $401.

Read More

1 minute read

Baird Downgrades argenx to Neutral, Raises Price Target to $460

By Benzinga Newsdesk

Today, 10:03 AM

Baird analyst Joel Beatty downgrades argenx (NASDAQ:ARGX) from Outperform to Neutral and raises the price target from $374 to $460.

Read More

1 minute read

SVB Leerink Maintains Outperform on argenx, Raises Price Target to $428

By Benzinga Newsdesk

Today, 10:03 AM

SVB Leerink analyst Thomas Smith maintains argenx (NASDAQ:ARGX) with a Outperform and raises the price target from $404 to $428.

Read More

3 minute read

Daily Biotech Pulse: GSK’s Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion’s Schizophrenia Candidate

By Vandana Singh

Today, 10:03 AM

Here's a roundup of top developments in the biotech space over the last 24 hours: